intelliatx.com - NTLA Book Capitalization

Public company logo of intelliatx.com (NTLA)

Intellia Therapeutics (NTLA) focuses on genome research by outsourcing production and testing to third-party contractors, as confirmed by this price action chart. The company is diversifying its portfolio by developing methods to correct pathologies both in vivo and ex vivo. Despite support from industry behemoths, high R&D costs and the risk of side effects keep the indicator at 0.74.

intelliatx.com (NTLA) - Company Book Value from 07/04/2022 to 10/29/2026

Intellia Therapeutics, Inc. (NTLA) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Intellia Corp|NTLA - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Intellia Therapeutics Inc|NTLA - Enterprise Value
- book capitalization data:
Equity per Share Intellia Therapeutics|NTLA - Company Book Value|Capitalization to Book Value Ratio intelliatx.com|NTLA - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Intellia Therapeutics|NTLA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Intellia Therapeutics Inc|NTLA - Company Debts|Debt to Book Value Ratio Intellia Therapeutics Inc|NTLA - Company Long-Term Liabilities|Amount of Current Liabilities Intellia Therapeutics
Basic company analysis:Intellia Therapeutics
Mass-produced product of Intellia

High R&D expenditures at Intellia Therapeutics (NTLA) and stringent FDA oversight necessitate significant financial reserves. This metric is calculated as the difference between all assets and liabilities, determining the actual value of net equity. An increase in this value confirms the company's resilience against bankruptcy during prolonged clinical trials. It is critical for investors to monitor the balance between liquidity and capital efficiency. Analyzing the balance sheet capitalization allows for a real-time assessment of investment security.

Competitors of Intellia Therapeutics (NTLA)

TEM - Company Book Value|QGEN: Book Capitalization|ionispharma.com (IONS) - Book Capitalization|Book Capitalization Repligen (RGEN)|Accounting Capitalization RNA|Company Book Value CRISPR Therapeutics Corp CRSP|Accounting Capitalization GeneDx Corp (WGS)|Book Capitalization RARE (Ultragenyx Pharmaceutical)|Book Capitalization beamtx.com BEAM|Book Capitalization SRPT (Sarepta)|TWST: Book Valuation of Business|Company Book Value 10x Genomics Corp|Accounting Capitalization Stoke Corp|BioLife Solutions, Inc. (BLFS) - Company Net Assets|Total Net Assets wavelifesciences.com|Maze Therapeutics - Book Capitalization|Total Stockholders' Equity SION (Sionna Therapeutics, Inc.)|Company Book Value Prime Medicine Corp PRME|Taysha Corp - Company Book Value|QURE - Company Book Value|MGTX - Company Book Value|REGENXBIO - Book Capitalization|Solid Biosciences Inc (SLDB) - Book Valuation of Business|OCGN (Ocugen Corp) - Book Capitalization|Book Capitalization PacBio Corp (PACB)|Benitec Biopharma Inc. (BNTC) - Company Net Assets|Accounting Value of Company designtx.com DSGN|Company Net Assets Rocket Pharmaceuticals, Inc. (RCKT)|Total Net Assets 4DMT FDMT|Book Capitalization Lexeo (LXEO)|KRRO - Accounting Value of Company|Book Capitalization EDIT|SLN (silence-therapeutics.com) - Total Stockholders' Equity|PRQR - Company Book Value|Accounting Value of Company Codexis Bio|Book Capitalization SGMO|Book Capitalization NAUT (nautilus.bio)|Metagenomi, Inc. (MGX) - Company Book Value|Net Asset Value Precision BioSciences Inc. DTIL|GBIO (Generation Bio Corp) - Book Capitalization|Boundless Bio Inc. (BOLD) - Total Stockholders' Equity|XCUR: Company Net Assets|Book Capitalization Imunon|Phio Pharmaceuticals Corp (PHIO) - Company Net Assets|Total Net Assets Mustang Bio Corp|RNAZ (TransCode Therapeutics) - Book Capitalization|Book Valuation of Business bionanogenomics.com (BNGO)|Applied DNA - Book Capitalization|bluebird bio, Inc - Company Net Assets|Company Book Value IPA (ImmunoPrecise)|OMGA: Book Valuation of Business|Company Book Value Singular Genomics|Accounting Capitalization Regulus Therapeutics, Inc.|Syros (SYRS) - Company Net Assets|Total Net Assets TBIO|Company Book Value TRACON Pharmaceuticals (TCON)|Company Book Value unitybiotechnology.com (UBX)